Evidence map›Paper›PMID 27045237›Full record

ArticleZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences2016

[Association of neuroendocrine differentiation with progression and prognosis of gastric adenocarcinoma].

Fangying Xu, Qin Liu, Fengyan Han, Enping Xu, Maode Lai, Zhongsheng Zhao

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Fangying XuKey Laboratory of Disease Proteomics of Zhejiang Province, School of Basic Medical Sciences, Zhejiang University School of Medicine, Hangzhou 310058, China.
Qin LiuKey Laboratory of Disease Proteomics of Zhejiang Province, School of Basic Medical Sciences, Zhejiang University School of Medicine, Hangzhou 310058, China.
Fengyan HanKey Laboratory of Disease Proteomics of Zhejiang Province, School of Basic Medical Sciences, Zhejiang University School of Medicine, Hangzhou 310058, China.
Enping XuKey Laboratory of Disease Proteomics of Zhejiang Province, School of Basic Medical Sciences, Zhejiang University School of Medicine, Hangzhou 310058, China.
Maode LaiKey Laboratory of Disease Proteomics of Zhejiang Province, School of Basic Medical Sciences, Zhejiang University School of Medicine, Hangzhou 310058, China.
Zhongsheng ZhaoDepartment of Pathology, Zhejiang Provincial People's Hospital, Hangzhou 310014, China.
Zhejiang Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the association of neuroendocrine differentiation with progression and prognosis of gastric adenocarcinoma.

methodsClinicopathological data of 240 patients with gastric adenocarcinomas were retrospectively analyzed. The expression of chromogranin A, synaptophysin and secrectagogin in cancer tissue was assessed by immunohistochemistry. The association of neuoroendocrine differentiation parameters with disease progression and survival of patients was analyzed.

resultsThe expression of synaptophysin was positively correlated with depth of invasion and secretagogin more often expressed in cases with lymph node metastasis. In Lauren diffuse type of cancer, expression of chromogranin A and secretagogin was unfavorable prognostic predictor. In TNM stage II adenocarcinoma, expression of chromogranin A and synaptophysin related to poor survival, and multivariate Cox proportional hazard model showed that synaptophysin was an independent predictor for poor survival.

conclusionNeuroendocrine differentiation predicts deeper depth of invasion, more possibility of lymph node metastasis and poor survival in gastric adenocarcinoma.

Indexed as

AdenocarcinomaBiomarkers, TumorChromogranin ADisease ProgressionHumansImmunohistochemistryLymphatic MetastasisNeoplasm StagingNeuroendocrine TumorsPrognosisProportional Hazards ModelsRetrospective StudiesSecretagoginsStomach NeoplasmsSynaptophysinBiomarkers, TumorChromogranin ASCGN protein, humanSecretagoginsSynaptophysin

Identifiers

PMID27045237
PMCPMC10400834
OpenAlexW2438266230

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.